Autologous CMV-Specific T Cells Are a Safe Adjuvant Immunotherapy for Primary GBM
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Autologous CMV-Specific T Cells Are a Safe Adjuvant Immunotherapy for Primary Glioblastoma Multiforme
J. Clin. Invest. 2020 Aug 04;[EPub Ahead of Print], C Smith, KE Lineburg, JP Martins, G Ambalathingal, MA Neller, B Morrison, KK Matthews, S Rehan, P Crooks, A Panikkar, L Beagley, L Le Texier, S Srihari, D Walker, R KhannaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.